Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

Karin B. Olson, C. Michael Hellie, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

Original languageEnglish (US)
JournalUrology
Volume66
Issue number3
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

zoledronic acid
Osteonecrosis
Jaw
Prostatic Neoplasms
Diphosphonates
Hormones
Bisphosphonate-Associated Osteonecrosis of the Jaw
Tooth Extraction
Bone Diseases
Osteoporosis
Tooth
Bone and Bones
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. / Olson, Karin B.; Hellie, C. Michael; Pienta, Kenneth.

In: Urology, Vol. 66, No. 3, 09.2005.

Research output: Contribution to journalArticle

@article{1781de28044146638d527cd213b1d209,
title = "Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid",
abstract = "Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.",
author = "Olson, {Karin B.} and Hellie, {C. Michael} and Kenneth Pienta",
year = "2005",
month = "9",
doi = "10.1016/j.urology.2005.03.028",
language = "English (US)",
volume = "66",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

AU - Olson, Karin B.

AU - Hellie, C. Michael

AU - Pienta, Kenneth

PY - 2005/9

Y1 - 2005/9

N2 - Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

AB - Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

UR - http://www.scopus.com/inward/record.url?scp=24144465755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144465755&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.03.028

DO - 10.1016/j.urology.2005.03.028

M3 - Article

VL - 66

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -